rHEALTH Targets $323 Billion Diagnostics Market with NASA-Backed Testing Tech

rHEALTH is seeking to disrupt the global blood diagnostics market with a portable, lab-quality testing device designed for use in extreme environments and private homes. Originally developed to monitor astronaut health on the International Space Station, the platform aims to address a critical gap in healthcare access affecting billions globally. The World Health Organization estimates that 4.5 billion people lack timely access to diagnostic testing, often resulting in significant delays in care. In the United States, this issue particularly impacts the more than 194 million adults managing chronic conditions. rHEALTH's solution utilizes a self-collected blood sample to provide results in approximately 20 minutes. The company holds 17 U.S. patents covering its device architecture, diagnostic algorithms, and miniaturized components. To date, rHEALTH has secured over $20 million in non-dilutive funding and established strategic partnerships with major institutions, including the Mayo Clinic, Boston Children’s Hospital, and AstraZeneca. From a market perspective, the company is targeting a total addressable market of $323 billion, with a specific focus on a $16.2 billion obtainable market for hematology diagnostics. rHEALTH expects to achieve FDA registration within the next 12 months, utilizing a revenue model based on device sales, disposable test cartridges, and software subscriptions.